Management of Uveitis in Spondyloarthropathy: Current Trends

Overview

Journal Perm J

Specialties General Medicine
Health Services

Date 2017 Dec 23

PMID 29272246

Citations 4

Authors

Nikhil Gupta

Aditi Agarwal

Affiliations

Soon will be listed here.

Abstract

Spondyloarthritis is a chronic inflammatory disease predominantly affecting joints of the axial skeleton. However, as many as 50% of patients with this disease may have extra-articular manifestations, which include uveitis; psoriasis; inflammatory bowel disease such as Crohn disease or ulcerative colitis; cardiovascular manifestations in the form of conduction abnormalities, atherosclerosis, or valvular heart disease; pulmonary involvement; and rarely renal involvement. Uveitis occurs in 25% to 40% of patients with spondyloarthritis. Management of uveitis is crucial to prevent morbidity caused by vision loss and secondary complications. Treatment ranges from local therapies to systemic drugs and varies depending on the severity and response to treatment. Categories of medical treatment include nonsteroidal anti-inflammatory agents, corticosteroids, and steroid-sparing agents. Biologic therapies such as antitumor necrosis factor agents act early in the disease process and have revolutionized the field of rheumatology, including management of uveitis. This review will focus on the management of ophthalmic manifestations in spondyloarthropathies.

Citing Articles

A large meta-analysis identifies genes associated with anterior uveitis.

Gelfman S, Moscati A, Huergo S, Wang R, Rajagopal V, Parikshak N Nat Commun. 2023; 14(1):7300.

PMID: 37949852 PMC: 10638276. DOI: 10.1038/s41467-023-43036-1.

Ocular Manifestations of Spondyloarthritis.

Pandey A, Ravindran V Mediterr J Rheumatol. 2023; 34(1):24-29.

PMID: 37223599 PMC: 10201097. DOI: 10.31138/mjr.34.1.24.

Impact of Climate Change on Eye Diseases and Associated Economical Costs.

Echevarria-Lucas L, Senciales-Gonzalez J, Medialdea-Hurtado M, Rodrigo-Comino J Int J Environ Res Public Health. 2021; 18(13).

PMID: 34281132 PMC: 8297364. DOI: 10.3390/ijerph18137197.

Recommendation for the Management of Spondyloarthritis Patients in Kuwait.

Ali Y, Abutiban F, Alawadhi A, Aldei A, Alenizi A, Alhajeri H Open Access Rheumatol. 2020; 12:147-165.

PMID: 32903931 PMC: 7445633. DOI: 10.2147/OARRR.S246246.

References

Kempen J, Altaweel M, Holbrook J, Jabs D, Sugar E . The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010; 149(4):550-561.e10. PMC: 2975449. DOI: 10.1016/j.ajo.2009.11.019. View

Daniel E, Thorne J, Newcomb C, Pujari S, Kacmaz R, Levy-Clarke G . Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149(3):423-32.e1-2. PMC: 2826576. DOI: 10.1016/j.ajo.2009.09.026. View

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M . A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2011; 22(2):298-302. DOI: 10.1007/s10165-011-0497-5. View

Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M . Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006; 65(12):1631-4. PMC: 1798480. DOI: 10.1136/ard.2006.052092. View

Munoz-Fernandez S, Martin-Mola E . Uveitis. Best Pract Res Clin Rheumatol. 2006; 20(3):487-505. DOI: 10.1016/j.berh.2006.03.008. View

Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K . Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2006; 66(4):548-50. PMC: 1856052. DOI: 10.1136/ard.2006.058248. View

Fiorelli V, Bhat P, Foster C . Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010; 18(2):116-20. DOI: 10.3109/09273941003587558. View

Jaffe G . Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008; 145(4):667-675. DOI: 10.1016/j.ajo.2007.11.008. View

Wendling D, Paccou J, Berthelot J, Flipo R, Guillaume-Czitrom S, Prati C . New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011; 41(3):503-10. DOI: 10.1016/j.semarthrit.2011.05.005. View

10.

Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster C . Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005; 13(2-3):205-12. DOI: 10.1080/09273940590933511. View

11.

Braun J, Baraliakos X, Listing J, Sieper J . Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52(8):2447-51. DOI: 10.1002/art.21197. View

12.

Helmick C, Felson D, Lawrence R, Gabriel S, Hirsch R, Kwoh C . Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008; 58(1):15-25. DOI: 10.1002/art.23177. View

13.

Trevisani V, Mattos K, Esteves R, Olialves S, Andrade L . Autoantibodies specificity in acute anterior uveitis according to the presence of the HLA-B27 allele. Ocul Immunol Inflamm. 2002; 9(4):231-42. DOI: 10.1076/ocii.9.4.231.3952. View

14.

Martin T, Smith J, Rosenbaum J . Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002; 14(4):337-41. DOI: 10.1097/00002281-200207000-00001. View

15.

Kuppermann B, Blumenkranz M, Haller J, Williams G, Weinberg D, Chou C . Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125(3):309-17. DOI: 10.1001/archopht.125.3.309. View

16.

Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V . Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2013; 22(2):90-5. DOI: 10.3109/09273948.2013.844265. View

17.

Howe L, Stanford M, Edelsten C, Graham E . The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye (Lond). 1994; 8 ( Pt 4):443-7. DOI: 10.1038/eye.1994.105. View

18.

Rodriguez A, Akova Y, Pedroza-Seres M, Foster C . Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology. 1994; 101(7):1267-74. DOI: 10.1016/s0161-6420(94)31179-1. View

19.

van der Horst-Bruinsma I, Nurmohamed M . Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012; 4(6):413-22. PMC: 3512172. DOI: 10.1177/1759720X12458372. View

20.

Vazquez-Cobian L, Flynn T, Lehman T . Adalimumab therapy for childhood uveitis. J Pediatr. 2006; 149(4):572-5. DOI: 10.1016/j.jpeds.2006.04.058. View